` BNR (Burning Rock Biotech Ltd) vs S&P 500 Comparison - Alpha Spread

BNR
vs
S&P 500

Over the past 12 months, BNR has underperformed S&P 500, delivering a return of -43% compared to the S&P 500's 9% growth.

Stocks Performance
BNR vs S&P 500

Loading
BNR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BNR vs S&P 500

Loading
BNR
S&P 500
Difference
www.alphaspread.com

Performance By Year
BNR vs S&P 500

Loading
BNR
S&P 500
Add Stock

Competitors Performance
Burning Rock Biotech Ltd vs Peers

S&P 500
BNR
ABBV
AMGN
GILD
VRTX
Add Stock

Burning Rock Biotech Ltd
Glance View

Market Cap
40.7m USD
Industry
Biotechnology

Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

BNR Intrinsic Value
15.47 USD
Undervaluation 76%
Intrinsic Value
Price
Back to Top